[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chirurgical-intervention\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chirurgical-intervention":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,72],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100614366","phase-2-preoperative-use-of-romiplostim-in-thrombocytopenic-patients-undergoing-cardiac-surgery-100614366",false,"NCT07278661","Preoperative Use of Romiplostim in Thrombocytopenic Patients Undergoing Cardiac Surgery.","Preoperative Use of Romiplostim in Thrombocytopenic Patients Undergoing Cardiac Surgery. A Phase 3, Multicenter Randomized Double-blinded Controlled Against Placebo Study.","CT-PLATE","Inclusion Criteria:\n\n* Adult patients with no upper age limit,\n* Scheduled cardiac surgery with cardiopulmonary bypass,\n* Patients with preoperative thrombocytopenia strictly \\\u003C150,000\u002Fmm3\n* Surgery performed with a blood recovery system using centrifugation (Cell Saver type) or equivalent,\n* Feasibility of a first injection (Romiplostim or Placebo) between D-14 and D-10 before surgery,\n* Surgery requiring the administration of antiplatelet and\u002For anticoagulant therapy for a minimum of 1 month postoperatively.\n\nExclusion Criteria:\n\n* Inability to administer the first injection of Romiplostim or Placebo within 10 days prior to surgery,\n* Cardiac surgery without cardiopulmonary bypass,\n* Coronary artery bypass grafting due to one or more significant coronary stenoses,\n* Tangential filtration blood recovery system (i-SEP SAME® type) planned for intraoperative use or absence of intraoperative blood recovery system due to investigator choice or availability issues,\n* Planned use of aprotinin as an antifibrinolytic agent during surgery,\n* Patient with contraindication to discontinuation of all antiplatelet therapy before surgery (with discontinuation at least 3 days before surgery for acetylsalicylic acid and at least 5 days before surgery for clopidogrel\u002Fticagrelor),\n* Hereditary or acquired thrombophilia with or without a history of thrombosis,\n* History of ischemic or hemorrhagic stroke,\n* History of phlebitis, pulmonary embolism, or portal vein thrombosis,\n* History of heart attack with stent placement less than one year ago,\n* Current limb immobilization (e.g., plaster cast for ankle fracture) or inability to walk independently due to limited mobility (e.g., paralysis),\n* Current immobilization of a limb (e.g., plaster cast for ankle fracture) or inability to walk independently due to motor limitation (e.g., complete paralysis of a limb) or medical contraindication (e.g., strict bed rest required),\n* Myelogram indicating malignant hematological disease or blast cells strictly greater than 5%,\n* Malignant diseases with last follow-up indicating disease progression,\n* Severe chronic liver disease with a CHILD-PUGH score \\> 6 (measured without decompensation),\n* Treatment with thrombopoietin receptor agonist received within 3 months prior to inclusion,\n* Treatment with JAK2 inhibitor currently underway or within the last month,\n* Treatment with Rituximab within the last 7.5 months or intravenous immunoglobulin within the last 40 days,\n* Ongoing treatment with corticosteroids at doses equal to or greater than 20mg of hydrocortisone, 5mg of prednisone\u002For prednisolone, 4mg of methylprednisone, or 0.75mg of dexamethasone,\n* Known hemophilia,\n* Hypersensitivity to romiplostim or any of its excipients, or to proteins derived from E. coli,\n* Context of hyperchloremia, hypernatremia, or major water and salt retention with anasarca refractory to medical treatment,\n* Pregnant women or women of childbearing age who are not using effective contraception,\n* Currently using combined oral contraceptive pills or oral hormone replacement therapy containing estrogen,\n* Breastfeeding women,\n* Minors,\n* Adults under guardianship, curatorship, or judicial protection,\n* Patients who do not speak French,\n* Patients without Social Security coverage.","ALL","18 Years",{"count":20,"type":21},136,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Romiplostim has demonstrated its efficacy and good tolerance in multiple indications. If the efficacy of Romiplostim is confirmed in this population, thrombocytopenic patients will be able to undergo cardiac surgery, which is generally life-saving, without prior thrombocytopenia.\n\nPatients included in the study will be hospitalized within 15 days of the first administration of the study treatment and will be closely monitored clinically and biologically for at least 10 days after surgery. The occurrence of an adverse event can therefore be quickly detected and managed.\n\nCollectively, \"Patient Blood Management\" strategies are mainly focused on the management of preoperative anemia. If positive, this study will enrich the therapeutic arsenal available for optimizing patients in preparation for major surgery. As no major collective complications are expected, the collective benefit\u002Frisk ratio also appears favorable.",[27,28],"Chirurgical Intervention","Thrombocytopaenia",[30,31,32,33],"Thrombocytopenia","Cardiac Surgery","Growth Factor","Patient Blood Management","RECRUITING","2026-03-31",{"date":37,"type":38},"2026-04-06","ACTUAL",{"date":40,"type":21},"2026-09-01",{"date":42,"type":21},"2028-12-01",{"name":44,"class":45},"Nantes University Hospital","OTHER",8,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100597719","evaluation-of-the-effect-of-reiki-on-pain-after-spinal-fusion-100597719","NCT07062146","Evaluation of the Effect of Reiki on Pain After Spinal Fusion","Evaluation of the Effect of Reiki on Pain After Spinal Fusion: A Comparative, Randomized, Pilot Study","REDAL","Inclusion Criteria:\n\n* \\- Subject aged 18 years or older;\n* Referred for a lumbar fusion of up to 3 levels.\n* Absence of participation in another clinical study.\n* Subject affiliated with a social security scheme or beneficiary of such a scheme\n\nExclusion Criteria:\n\n* Neuropathic patient\n* Presence of neuropathic pain\n* Diagnosis of fibromyalgia\n* Received therapeutic touch, polarity therapy, or professional massage therapy in the past four weeks\n* Unable to undergo medical follow-up for the study\n* Adult subject protected by law, under guardianship or trusteeship","75 Years",{"count":57,"type":21},60,[59],"NA","This study involves patients undergoing lumbar spine surgery (lumbar arthrodesis). It compares the effects of Reiki, an energy-based therapy, with conventional approaches to relieve postoperative pain.\n\nThe goal is to determine whether this non-drug method can help reduce pain, limit the use of painkillers, and enhance patient comfort during recovery.",[27],"2026-02-03",{"date":64,"type":38},"2026-02-04",{"date":66,"type":38},"2025-09-09",{"date":68,"type":21},"2026-07-28",{"name":70,"class":45},"Clinique Bizet",1,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":71},"100577732","effects-of-osteopathic-management-on-disability-and-quality-of-life-after-lumbar-arthrodesis-100577732","NCT06802120","Effects of Osteopathic Management on Disability and Quality of Life After Lumbar Arthrodesis","Effects of Osteopathic Management on Disability and Quality of Life After Lumbar Arthrodesis. A PARALLEL, RANDOMIZED AND DOUBLE-BLIND CONTROLLED PILOT STUDY","OSTEODESE","Inclusion Criteria:\n\n* having experienced a lumbar arthrodesis (of one to three levels) four weeks before inclusion\n* being under a stable pharmacological treatment over the last month\n* who are suffering from postoperative mechanical pain (VAS ≥ 4)\n\nExclusion Criteria:\n\n* neuropathic pain according to a DN4 score greater than or equal to 4\u002F10,\n* are suffering from fibromyalgia,\n* algodystrophy,\n* other somatic or neuropsychiatric diseases (other than depression and anxiety),\n* have received osteopathic treatment over the last three month prior to inclusion,\n* are included in another interventional research protocol during the study period",{"count":81,"type":21},40,[59],"The aim of our study is to assess the effect of a combined physiotherapy and osteopathy treatment versus a placebo on the management of disability and quality of life after lumbar arthrodesis. This study will provide a better assessment of the use of osteopathy as a non pharmacological approach to post-operative management.\n\nFor this purpose, We will analyze the effects of these two approaches, targeted and non-targeted osteopathy (TO vs. NTO), on patients' disability and quality of life after surgery.",[27],"2026-01-02",{"date":87,"type":38},"2026-01-06",{"date":89,"type":38},"2025-01-02",{"date":91,"type":21},"2027-05",{"name":70,"class":45}]